Analysis of promoter hypermethylation of p16 gene in sera from primary liver cancer patients
CHEN Long-bang~1, LIN Qing~1, TANG Yong-ming~2, WANG Jing~(2)(1. Department of Oncology, Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing 210002,Jiangsu,China; 2.Laboratory of Clinical Immunology, the 454th Hospital of PLA, Nanjing 210002,Jiangsu,China)
Objective:To analyze the aberrant methylation of p16 gene in sera from primary liver cancer patients and to evaluate the clinical significance. Methods:A methylation-specific PCR was performed for the detection of promoter hypermethylation of p16 gene in blood DNA from 64 cases of PLC patients,and to anamyze the relationship between the aberrant methylation of p16 gene and the clinical pathological data . Results:76.6%(49/64)of the sera from 64 cases of PLC patients showed hypermethylation for p16 promoter,whereas no methylated p16 gene promoter were found in sera from liver benign diseases patients and normal control. Methylated p16 gene promoter in sera did not strongly correlated with HBsAg, AFP,stage ,metastasis and differentiation in PLC. Conclusion:Detection of the aberrant methylation of p16 gene in blood DNA from PLC patients might offer an effective means for the earlier auxillary diagnosis of the malignancy.